Publications by authors named "B Ziman"

Background: Histone modification H3K27me3 plays a critical role in normal development and is associated with various diseases, including cancer. This modification forms large chromatin domains, known as Large Organized Chromatin Lysine Domains (LOCKs), which span several hundred kilobases.

Result: In this study, we identify and categorize H3K27me3 LOCKs in 109 normal human samples, distinguishing between long and short LOCKs.

View Article and Find Full Text PDF
Article Synopsis
  • UASCC is a highly aggressive cancer characterized by elevated methionine levels, driven by the LAT1 transporter, which is uniquely activated in this type of cancer.
  • Research identifies EZH2 as a critical target downstream of the LAT1-methionine pathway, linking methionine metabolism to epigenomic changes essential for tumor growth.
  • Targeting this LAT1-methionine-EZH2 cascade through drugs or dietary changes presents a promising therapeutic strategy for UASCC.
View Article and Find Full Text PDF

Squamous cell carcinomas (SCCs) are common and aggressive malignancies. Immune check point blockade (ICB) therapy using PD-1/PD-L1 antibodies has been approved in several types of advanced SCCs. However, low response rate and treatment resistance are common.

View Article and Find Full Text PDF

Unlike most cancer types, the incidence of esophageal adenocarcinoma (EAC) has rapidly escalated in the western world over recent decades. Using whole genome bisulfite sequencing (WGBS), we identify the transcription factor (TF) FOXM1 as an important epigenetic regulator of EAC. FOXM1 plays a critical role in cellular proliferation and tumor growth in EAC patient-derived organoids and cell line models.

View Article and Find Full Text PDF

ARID1A, a member of the chromatin remodeling SWI/SNF complex, is frequently lost in many cancer types, including esophageal adenocarcinoma (EAC). Here, we study the impact of ARID1A deficiency on the anti-tumor immune response in EAC. We find that EAC tumors with ARID1A mutations are associated with enhanced tumor-infiltrating CD8 T cell levels.

View Article and Find Full Text PDF